for thank for results call. Well, everyone you thank joining our and us afternoon, you, Beth, third good and quarter
For the describes provide is this. These core the the DNA markets, strong to drives describe qualifiers interest. investors combination is science, vision huge that me combination their Applied great told of Applied Opportunity its It DNA with for that and at many and IP. the by a Trifecta literally three biotech team our the and reason company, is
phrase indicator with revenue. Our recognized revenue that of our large protector of a strategy I’ve Booked commercial a combines truer progress together. coming a you in before ecosystems, as with talking steadily is used is is revenue deferred it
the booked in our orders from $X.X This two that future for though, of be this approximately in was recognized quarters. last QX million. revenue booked XXXX, were follows most quarter $X.X strong even revenue which the years of approximately Our million at strongest must
evidence is sales Our markets of by desperate our strong and back-to-back performance adoption. growing platform’s quarterly powered
easy improving continue. being not it’s steadily trend that disruptive. and our uptake believe But we Now strongly will is
just flow our the naturally the Reaction centered most done assays reaction the using The Now, from our in in cell mechanics made the in unique precursors, patents. platform of bring than assays and steady PCR improvements DNA voluminous scale scale clinic, me. the increase and portfolio reaction this our price this they same but of DNA sometimes barely reproduces Applied arose liquid, enough to even software microliters we more or to decreasing increasing and of performed to nucleus the to in ability to DNA inventions the see. in the of the which ability very scale liter in fluidics, produce Chain and excuse the advancements a in about develops to chemistry volume design their with biochemistry are strong ubiquitous the a Polymerase PCR. behind continuous large-scale protected instrumentation, is million-fold or the of
reaction of which one a its of and of which we into is as nucleus. industry. Just suited the enhance DNA use traditional plasmid therapies, That chemical our which viral In into tools large-scale purely we for control and gene withins this have sized and of therapies, addition traditional DNA, in business it’s knowhow to the modification the biochemical PCR transfer linear is the in producing ligands peptide making gene vectors, both to amplicon fermentation. used impurities of the at or amplicons established or the ways products from the contrast of bacterial the are production that we cellular of therapeutics be well sized, to uptick accompany introduction especially used these are other to cytoplasm by the to be a methods the important, Biopharma of cancer vaccines mitigate the use like highly or beneficial where and reaction
our so to ensure can tags our modifications remain taggant in we are really and in DNA superb PCR As meant modalities of vertical have business, be essential and equaled - while used performance formulations are at in PCR chemistries have bound scale-ups, to chemical - industrial to the authentication. done the with the protect to me we they job a our excuse fit every detection to material that that
Cannabis and palm us portable, We that Association your quicker. Industry in hand We internet-accessible at PCR have authentication by on platform literally powered our to of more recently another introduced an the new iPhone. sits approach the field that new Conference stepping makes smaller, a
future you to this more calls. in tell have about will We
our Over we and we demand over Therapeutics expansion DNA we I to sorry, challenges some we’ve of advanced will growth platform. in sustained had and strategy profitability years, business, that business, how the a technology products. and insight our to past the you today, never steadily in commercial disruptive deepen the on by – for we’ll our place brief this growing executed advanced next In revenue customers. higher the supply and proposition years, breaking global been have rollout has our discuss a diligently a time, have new In are that Diagnostics of us value few the to puts worked on proposition few capture partners our opportunities steadily taggant our the chain today we afforded path to give will value as us we have hear PCR believe stronger. and development In into
Now, and in textiles footprint we support our business for represent continue cotton it business growing market, position our quarter growth. The vertical. the addressable most to story synthetics as in is for established our this
third SigNature ginning coming historically for the signals demand of the our season. quarter start ahead DNA cotton the for taggant The cycle of T
on followed trends this our cotton announced XX is that growing. order present and July and signals So, demand historical
gold Our traceability. brand Pimacott a remains for standard
looking into footprint America’s is HomeGrown Bed home Beyond the by and today, & of expansion at Walk Wales, store brands sheeting the growing supported one are to along first politics stores. you based the cotton an system traceability the installed consumer South Our technology. and Australian Moree Dreyfus and in accessories increasing with cotton but in and we these stores. our taggant chain In ready gin number Australia. day Acala sustainable and also gin our in HomeGrown enjoying American is for be cotton wall, Bath match Pimacott partners upland SigNature This home ninth to to in and home made goods, DNA T tagged to pure demonstrating was Tagging Himatsingka New our retailer high-end sentiment and value the will in Louis as marketed on see are international non-sheeting May, Delta, Australian by tag HomeGrown also at with
to for several business and platform offer has the is traction verticals which directly gained several platform our CertainT Our applicable. that revenue across opportunity near-term adjacent markets
our forensic the we commercial laboratory testing quarter, customers our cotton services also replicating cotton Brook it began chain region. traversing offers many majority to operation prospective with of supply their the cotton in in utility India the puts Stony chains customers. The exclusive During supply Himatsingka in and in global of The our but to authentication partner, front to Group us Asia-Pacific region, India-based this greater facility provide support full right to partners,
authenticity also one From of data is spinning India-based exchanging now has in facility, sheeting construction manufacturer In than Himatsingka’s is Himatsingka’s test company T. was is throughout India market production in well of conference Last its responding traceability spinning presented exiting XXX goal. world’s we world. success. textile Brussels, at track how a one to April from with growing towel conferences from chain of largest and we brands leaders the central Himatsingka’s the increased goods largest Himatsingka’s now their to this visited its doubling Better we stakeholders sheeting, inviting to with to supports platform world will and The Cotton saw associations our more begun and team received of ability under IT Conference be only terry annual our interest tell to trace samples plans, CertainT and when SigNature In The capacity. cotton is the expansion success on with cotton Himatsingka our efficiency. plant the roof. major team cotton we market which its Initiative’s our Their initiatives. the presentation cotton Annual derive the capacity story. that facility year, supply well be A that it’s traceability in the over The completed year, can plant to of cotton system one and very ERP Belgium will manufacturers trade signals the year, share more completed. also Their Our for conclusion. a this commercial expansion know June
pilot the to with attention synthetic with year. incredible are our being need has focused near be of future. for with textiles will for increased carbon resources footprints, Now where and paid differentiation paid our the in problems plastics the a work by oceans The suppliers bulk this textile
partners Our the CertainT high and propositions Palmetto profile are and retailers established the value having with GHCL discussions others Loftex, platform. about
central but retail among them, the see hub targets. from As all the directions synergy marketing platform to of the we same the
world recyclable be in the PET home, of of a The positive. our across fibers, as initiatives relate tracking finished business textile We’ve taggant and among a In do of to and industry other development business for assist pleased just penetration who of renewable and fact, with have net in tagging, well for other recycled is very and chain in this over. apparel introduced and apparel that insider as we consultant that hired have are cotton, market supply former will we in he materials practice we our can growing collaborations additional impact brands announce to as and customers platform and we global used positioned some synthetic that. footwear. the known us to opportunities created market, of us head to has complex the working well-respected global our testing goods, number been To more of a front our that textiles assist believe operations our
these look convert into and we Over commercial opportunities to several orders. next quarters, the scale opportunities will
Moving Centre by BLC to and know, global of a and Technology leather sponsored completed project year. one you the feasibility our NGO Limited in two practice, five tanneries March on with successfully in this as large we Leather conjunction brands,
revenue this this ready the material in Our negotiating as trials additional fiscal all technology traceability XXXX. that performance In With we quarterly are leather provide quarter, harsh third and model others. tagging are commercial are from go our for second started with expected some forensic nicely clients leather trials with scale we we the on to in commercial to is to environment in industrial shop. place, tracking farm to of with half commercial as perhaps path to early consortium scale the
Our be cannabis projection for to efforts. a focus reach that it Within $XX It’s the us a well. key business our with could very of focus market along cannabis a recent continues to XXXX, industry billion moving by – market worthwhile on. remains
processors As the industry’s System real for Tagging Cannabis of to the Show NCIA Jose shown, San we at goods received end show The trace as at opportunities. conceptually the well as well dispensary cannabis have at prospects in-country of U.S. tagging and in physical export the owners. well markets track July. the as was as both strong for The are by interest business relative international first and the cultivators, in
refine next collectively will steps and to opportunities. with these and our continue other We timing potential
Sale its which not with programs Biotrace our at International partners, Our Systems. launched offering cannabis international integrated Seed selected be will new to that to or had platform. aimed offering, modular combined state-wide and yet TheraCann This recently CertainT Sale branded, tagging system as is ETCH Seed
also CertainT existing looking prominence physical tag a to already and their existing fit to for established prove are for to add solutions a system. a In addition, within where mechanism trace systems programs Seed and track opportunities be our Sale with are
qualification, market this additional agreements new sales colorants very our through of and momentum manufacturer. leading approvals, via partnership establish And last component and ink product to industry’s for regulatory our year second to important. and a Colorcon, pathways, three We in the marketing opportunities. access to with along coatings, basic strategy a growth growth commercial markets is continues which pharma enter Now, leverage
FDA are with global engaged is administrative when have the sales product authentication of It’s To for the the we large to quarter, commodities that technical year already new science. set development. steps manufacturer DNA way. in the milestones established by their the compliance eventuality sales Colorcon the in Colorcon’s with strategic Technical in seek signed regard the Europe for last marketing. product footprint, markets with inspection of in agreement the continues to is readiness regulatory with Following and ready second regulatory and May, on stage proven activities. on to approval continuing several in to sales products standard new tagging for in ACG, the Master traceability drive highly the a definitive based in close open tracks that in and and of feasibility testing, to after acceptance product and IDMS work a development, MOU. and regulatory Verification stability capsule initiated its commercialization aggressive chain UL Program and administrative pipeline. global been we have business us. Drug UL reaches candidates their to X largest teams work and a on mentioned. review team called out are capsule the File to the a customer management in that announced acceptance, the toward to you, with remind Colorcon MOU in extends those supply Discussions Type compliance also We’ve has underway Colorcon a its a Subsequent and target we and product With our UL pilot required conjunction partners I for partnership marketing SigNature and testing the globally, aligned of each
continuing implement initiatives as our are are platform. with We partnership within Videojet’s Videojet, and industry a which that are technology to championing cultivating evangelists marketing silos result in under are customers dialogue with our we UL several
tag, the platform the Now, pillars we our CertainT track. and of side of to build IT continue supporting test,
link execution and with We a implementation over with million managing for They Our recently partnerships both two leader announced up in technical us the as capacity business diamonds. see partnership a goods technology. teams vital both have Everledger between demonstrated with digital physical transactions. and large-scale blockchain-enabled
states, Everledger does asset it Founder does have Leanne as products In CEO value existence. authenticity, if not an or ownership As market, an identity, the prominence, an Kemp, high-end in and and not as the can’t blockchain-enabled a captured uniquely incorporating on well forensic separated. the asset, to can By track data we value layer provide platform. have our confidence be added identifying
Our tagging teams considered are currently combined to revenues on of for blockchain to events in with chain platform Other both both implementation both a initial development and the supply driving industry. networks from authentication of leather an a focus platforms be joint for companies companies. our can
the and for customers the contract therapeutics plasmids. three via we’ve research that new they of of Now, updated we a and the contract DNA quarters, progress were the of in previously last and In therapeutic applications us with to you quarters, three customers attracted have each I sourcing PCR. linear fermentation of collaborators for manufacture diagnostic last on and each manufacture our DNA by of production for coming bacterial
and risks therapies contamination do response the in patients. genome. toxin cell the three, and inflammatory therapies target the one, and gene potential number a DNA of of of for sequences for target contamination the the number sequences including the the DNA gene well-defined plasmid-based Number patients, host DNA However, a generalized bacterial contamination for of bacterial adaptive risk the plasmid two; antibiotic plasma pose from non-target resistance; by by risk of DNA of of risk
Medicines developing agreements European vitro adoptive PCR intellectual therapies groups cancer as development approved FDA RNA well-known recently produced more T which or vaccines. template and CAR Agency for we cooperative with production products. negotiating of any T-cell collaboration known the similar amplicons revenue We’ve property subsequent using share approved for vaccines, in as in and the already the are begun in We also
linear presenting We at the Massachusetts the our DNA capabilities at Oncology of Cambridge this in month. Conference will be Immuno end
So we are and of all of encouraged the hear in that hope will same. by signs these you summary, the we growth
And been Thank prepared this concludes our call Our for the open proposition value you. remarks. has never please Operator, stronger. questions.
